India · Delayed Price · Currency is INR Beta Drugs Statistics
Total Valuation
Beta Drugs has a market cap or net worth of INR 14.37 billion. The enterprise value is 14.60 billion.
| Market Cap | 14.37B |
| Enterprise Value | 14.60B |
Important Dates
The last earnings date was Friday, May 22, 2026.
| Earnings Date | May 22, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Beta Drugs has 10.09 million shares outstanding. The number of shares has increased by 0.43% in one year.
| Current Share Class | 10.09M |
| Shares Outstanding | 10.09M |
| Shares Change (YoY) | +0.43% |
| Shares Change (QoQ) | -0.06% |
| Owned by Insiders (%) | 1.05% |
| Owned by Institutions (%) | n/a |
| Float | 3.36M |
Valuation Ratios
The trailing PE ratio is 34.78.
| PE Ratio | 34.78 |
| Forward PE | n/a |
| PS Ratio | 3.73 |
| PB Ratio | 5.87 |
| P/TBV Ratio | 6.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 38.54 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.29, with an EV/FCF ratio of -90.14.
| EV / Earnings | 35.19 |
| EV / Sales | 3.79 |
| EV / EBITDA | 19.29 |
| EV / EBIT | 24.94 |
| EV / FCF | -90.14 |
Financial Position
The company has a current ratio of 3.10, with a Debt / Equity ratio of 0.60.
| Current Ratio | 3.10 |
| Quick Ratio | 2.26 |
| Debt / Equity | 0.60 |
| Debt / EBITDA | 1.95 |
| Debt / FCF | -9.13 |
| Interest Coverage | 3.82 |
Financial Efficiency
Return on equity (ROE) is 18.78% and return on invested capital (ROIC) is 17.44%.
| Return on Equity (ROE) | 18.78% |
| Return on Assets (ROA) | 7.85% |
| Return on Invested Capital (ROIC) | 17.44% |
| Return on Capital Employed (ROCE) | 15.10% |
| Weighted Average Cost of Capital (WACC) | 2.36% |
| Revenue Per Employee | 9.64M |
| Profits Per Employee | 1.04M |
| Employee Count | 399 |
| Asset Turnover | 0.83 |
| Inventory Turnover | 2.55 |
Taxes
In the past 12 months, Beta Drugs has paid 129.11 million in taxes.
| Income Tax | 129.11M |
| Effective Tax Rate | 23.74% |
Stock Price Statistics
The stock price has decreased by -24.65% in the last 52 weeks. The beta is -0.45, so Beta Drugs's price volatility has been lower than the market average.
| Beta (5Y) | -0.45 |
| 52-Week Price Change | -24.65% |
| 50-Day Moving Average | 1,308.23 |
| 200-Day Moving Average | 1,541.50 |
| Relative Strength Index (RSI) | 59.65 |
| Average Volume (20 Days) | 24,637 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Beta Drugs had revenue of INR 3.85 billion and earned 414.83 million in profits. Earnings per share was 40.92.
| Revenue | 3.85B |
| Gross Profit | 2.14B |
| Operating Income | 585.25M |
| Pretax Income | 543.94M |
| Net Income | 414.83M |
| EBITDA | 756.78M |
| EBIT | 585.25M |
| Earnings Per Share (EPS) | 40.92 |
Balance Sheet
The company has 1.25 billion in cash and 1.48 billion in debt, with a net cash position of -229.59 million or -22.74 per share.
| Cash & Cash Equivalents | 1.25B |
| Total Debt | 1.48B |
| Net Cash | -229.59M |
| Net Cash Per Share | -22.74 |
| Equity (Book Value) | 2.45B |
| Book Value Per Share | 241.55 |
| Working Capital | 2.27B |
Cash Flow
In the last 12 months, operating cash flow was 372.86 million and capital expenditures -534.82 million, giving a free cash flow of -161.95 million.
| Operating Cash Flow | 372.86M |
| Capital Expenditures | -534.82M |
| Depreciation & Amortization | 171.53M |
| Net Borrowing | 2.40M |
| Free Cash Flow | -161.95M |
| FCF Per Share | -16.04 |
Margins
Gross margin is 55.52%, with operating and profit margins of 15.21% and 10.78%.
| Gross Margin | 55.52% |
| Operating Margin | 15.21% |
| Pretax Margin | 14.13% |
| Profit Margin | 10.78% |
| EBITDA Margin | 19.67% |
| EBIT Margin | 15.21% |
| FCF Margin | n/a |
Dividends & Yields
Beta Drugs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.43% |
| Shareholder Yield | -0.43% |
| Earnings Yield | 2.89% |
| FCF Yield | -1.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 26, 2025. It was a forward split with a ratio of 1.05.
| Last Split Date | Mar 26, 2025 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |